Operating margins remain structurally negative, reverting to -16.5% in 2026Q1 after a temporary 52.2% peak in 2025Q3 driven by non-recurring milestone recognition.
| Sales/Revenue | 225.27M | 218.71M | 7M | 23.39M | 50.93M | 27.94M | 19.54M | 0 | 0 | 0 |
| Revenue Growth % | 3118.14% | 3024.43% | -70.07% | -54.08% | 82.28% | 43.01% | - | - | - | - |
| Cost of Goods Sold | 1.14M | 4.59M | 3.83M | 4.01M | 2.1M | 1.73M | 1.38M | 1.25M | 886K | 391K |
| COGS % of Revenue | - | 2.1% | 54.77% | 17.14% | 4.13% | 6.17% | 7.07% | - | - | - |
| Gross Profit | 224.13M | 214.12M | 3.17M | 19.38M | 48.83M | 26.22M | 18.16M | -1.25M | -886K | -391K |
| Gross Margin % | 99.49% | 97.9% | 45.23% | 82.86% | 95.87% | 93.83% | 92.93% | - | - | - |
| Gross Profit Growth % | - | 6663.01% | -83.66% | -60.32% | 86.26% | 44.39% | 1558.39% | -40.52% | -126.6% | - |
| Operating Expenses | 407.6M | 373.43M | 330.14M | 153.81M | 111.33M | 76.48M | 53.5M | 43.03M | 35.53M | 14.05M |
| OpEx % of Revenue | - | 170.74% | 4716.3% | 657.71% | 218.59% | 273.73% | 273.83% | - | - | - |
| Selling, General & Admin | 69.19M | 63.32M | 35.47M | 24.3M | 21.8M | 18.33M | 13.8M | 8.71M | 3.78M | 1.66M |
| SG&A % of Revenue | - | 28.95% | 506.69% | 103.9% | 42.8% | 65.59% | 70.65% | - | - | - |
| Research & Development | 339.54M | 314.7M | 294.67M | 129.51M | 89.54M | 58.16M | 39.7M | 34.32M | 31.75M | 12.38M |
| R&D % of Revenue | - | 143.89% | 4209.61% | 553.81% | 175.8% | 208.15% | 203.18% | - | - | - |
| Other Operating Expenses | -1000K | -4.59M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -183.47M | -159.31M | -326.98M | -134.43M | -62.5M | -50.27M | -35.34M | -44.27M | -36.42M | -14.44M |
| Operating Margin % | -81.44% | -72.84% | -4671.07% | -574.85% | -122.72% | -179.91% | -180.9% | - | - | - |
| Operating Income Growth % | - | 51.28% | -143.23% | -115.08% | -24.34% | -42.23% | 20.16% | -21.57% | -152.23% | - |
| EBITDA | -178.87M | -154.72M | -323.14M | -130.42M | -60.4M | -48.54M | -33.96M | -43.03M | -35.53M | -14.05M |
| EBITDA Margin % | -79.4% | -70.74% | -4616.3% | -557.71% | -118.59% | -173.73% | -173.83% | - | - | - |
| EBITDA Growth % | 49.82% | 52.12% | -147.77% | -115.93% | -24.43% | -42.93% | 21.06% | -21.09% | -152.94% | - |
| D&A (Non-Cash Add-back) | 4.6M | 4.59M | 3.83M | 4.01M | 2.1M | 1.73M | 1.38M | 1.25M | 886K | 391K |
| EBIT | -183.47M | -159.31M | -274.48M | -112.96M | -58.66M | -49.76M | -34.49M | -41.98M | -34.35M | -11.86M |
| Net Interest Income | 43.41M | 45.62M | 52.5M | 21.47M | 3.85M | 506K | 849K | 2.29M | 1.99M | 150K |
| Interest Income | 43.41M | 45.62M | 52.5M | 21.47M | 3.85M | 506K | 849K | 2.29M | 1.99M | 150K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 43.41M | 45.62M | 52.5M | 21.47M | 3.85M | 506K | 849K | 2.3M | 2.07M | 2.58M |
| Pretax Income | -140.06M | -113.7M | -274.48M | -112.96M | -58.66M | -49.76M | -34.49M | -41.98M | -34.35M | -11.86M |
| Pretax Margin % | -62.17% | -51.99% | -3921.1% | -483.05% | -115.17% | -178.1% | -176.55% | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -140.06M | -113.7M | -274.48M | -112.96M | -58.66M | -49.76M | -34.49M | -41.98M | -34.35M | -11.86M |
| Net Margin % | -62.17% | -51.99% | -3921.1% | -483.05% | -115.17% | -178.1% | -176.55% | - | - | - |
| Net Income Growth % | 54.28% | 58.58% | -142.98% | -92.59% | -17.87% | -44.26% | 17.82% | -22.21% | -189.55% | - |
| Net Income (Continuing) | -140.06M | -113.7M | -274.48M | -112.96M | -58.66M | -49.76M | -34.49M | -41.98M | -34.35M | -11.86M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.58 | -1.28 | -3.36 | -1.96 | -1.42 | -1.41 | -1.31 | -1.90 | -2.41 | -0.83 |
| EPS Growth % | 55.43% | 61.9% | -71.43% | -38.03% | -0.71% | -7.63% | 31.05% | 21.16% | -190.36% | - |
| EPS (Basic) | - | -1.28 | -3.36 | -1.96 | -1.42 | -1.41 | -1.31 | -1.90 | -2.41 | -0.83 |
| Diluted Shares Outstanding | 88.7M | 88.49M | 81.68M | 57.52M | 41.44M | 35.25M | 24.72M | 20.23M | 14.24M | 14.24M |
| Basic Shares Outstanding | 88.7M | 88.49M | 81.68M | 57.52M | 41.44M | 35.25M | 24.72M | 20.23M | 14.24M | 14.24M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
Clinical Milestone Dependency
As indicated by the company's financial history, revenue growth is entirely non-linear, characterized by a massive $207.8 million spike in 2025Q3 followed by a return to negligible levels, confirming that top-line performance is driven by episodic collaboration milestones rather than recurring commercial product sales or organic growth.
The extreme volatility in quarterly revenue suggests that investors should disregard traditional growth metrics, as the figures reflect accounting recognition of partnership events rather than operational scale. This reliance on milestone-based revenue creates significant forecasting uncertainty and highlights the company's current status as a pre-commercial research entity.
According to the provided income statements, R&D expenditures have climbed steadily from $38.8 million in 2023Q4 to $95.7 million by 2026Q1, demonstrating a persistent commitment to clinical advancement that consistently dwarfs the company's intermittent revenue inflows and underscores a high-burn operational model.
The upward trend in R&D spending reflects the increasing costs associated with advancing multiple Phase I/II programs simultaneously. This expense structure appears to be the primary driver of the company's negative operating margins, necessitating a constant focus on capital preservation and external funding.
Based on reported figures, the company's operating margin reached a peak of 52.2% in 2025Q3 due to one-time milestone recognition, yet it reverted to -16.5% in 2026Q1, illustrating that the business lacks the structural operating leverage required to sustain profitability without significant, recurring external collaboration payments.
The inability to maintain positive operating margins during non-milestone quarters suggests that the current cost base is not yet optimized for self-funding. Investors should monitor whether future clinical data readouts can trigger further milestone payments to offset these substantial, fixed-cost operating expenses.
As noted in the quarterly data, stock-based compensation reached $12.2 million in 2025Q3, representing a significant non-cash expense that complicates the assessment of the company's underlying cash burn and dilutive impact on shareholders during periods of intense clinical development activity.
The reliance on equity-based incentives for talent retention adds a layer of complexity to the income statement, as these costs do not immediately impact cash reserves but do dilute existing equity holders. Analysts should adjust for these non-cash items to better understand the true economic cost of the company's research operations.
Quick answers to the most common questions about buying IDYA stock.
For fiscal year 2025, IDEAYA Biosciences, Inc. (IDYA) reported total revenue of $218.7M.
IDEAYA Biosciences, Inc. (IDYA) reported a net loss of $113.7M for the fiscal year ending 2025.
IDEAYA Biosciences, Inc. (IDYA) reported an operating income of $-159.3M, resulting in an operating profit margin of -72.8%. This margin reflects the operational efficiency of the business before interest and taxes.
IDEAYA Biosciences, Inc. (IDYA) generated $214.1M in gross profit for the year, representing a gross profit margin of 97.9%. This demonstrates the company's core pricing power and production efficiency.